pharmaceutical daily

Phenylketonuria (PKU) – Pipeline Insight, 2019 –

DUBLIN–(BUSINESS WIRE)–The “Phenylketonuria
(PKU) – Pipeline Insight, 2019”
drug pipelines has been added
to’s offering.

The report offers comprehensive insights of the pipeline (under
development) therapeutics scenario and growth prospects across
Phenylketonuria (PKU) development.

The report provides detailed coverage of the pipeline landscape for this
mechanism of action, equipped with data from multiple sources with
complete pipeline analysis by developmental stage, associated
indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental

Pipeline therapeutics development coverage provides descriptive product
profiles including (but not limited to) drug description, product
development and R&D activities encompassing clinical and pre-clinical
studies, designations, collaborations, licensing deals, grants,
technologies and patent details.

Scope of the Report

Reasons to Buy

Companies Mentioned

Key Topics Covered

1. Report Introduction

2. Phenylketonuria (PKU) Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Products in Clinical Stage

6. Products in Pre-Clinical and Discovery Stage

7. Therapeutic Assessment

8. Inactive Products

For more information about this drug pipelines report visit

Laura Wood, Senior Press Manager

E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900

Topics: Endocrine
and Metabolic Disorders Drugs

Exit mobile version